Breaking News
0

Mylan NV (MYL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Mylan's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
19.09 0.00    0.00%
21/08 - Closed. Currency in USD ( Disclaimer )
After Hours
19.25
+0.16
+0.84%
17:28:21 - Real-time Data
Type: Equity
Market: United States
ISIN: NL0011031208 
CUSIP: 001103120
  • Volume: 3,855,831
  • Bid/Ask: 19.00 / 19.25
  • Day's Range: 18.87 - 19.35
Mylan 19.09 0.00 0.00%

MYL Overview

 
Information about the Mylan NV Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close19.09
Day's Range18.87 - 19.35
Revenue11.29B
Open19.19
52 wk Range16.63 - 39.59
EPS0.04
Volume3,855,831
Market Cap9.85B
Dividend (Yield)N/A (N/A)
Average Vol. (3m)8,082,029
P/E Ratio505.7
Beta1.81
1-Year Change - 50.74%
Shares Outstanding515,869,921
Next Earnings DateNov 11, 2019
What is your sentiment on Mylan?
or
Market is currently closed. Voting is open during market hours.

Mylan NV News


Mylan NV Analysis


Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Strong Sell Sell Buy Neutral Strong Sell
Technical Indicators Strong Sell Sell Strong Sell BUY Strong Sell
Summary Strong Sell Sell Neutral Neutral Strong Sell

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Completed Patterns
Bullish doji Star 1W 2 Aug 04, 2019
Engulfing Bearish 5H 3 Aug 20, 2019 02:00PM
Three Inside Up 30 5 Aug 21, 2019 01:00PM
Falling Three Methods 1M 10 Oct 18
Three Black Crows 1H 10 Aug 20, 2019 12:00PM

Mylan NV Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 19.09 19.00 19.25 3,855,831 0.00% USD 21/08  
  CBOE 19.07 0.00 0.00 0 0.00% USD 21/08  
  Berlin 16.892 16.986 17.424 0 -0.01% EUR 02:08:00  
  Stuttgart 17.254 17.500 17.700 0 0.00% EUR 21/08  
  Munich 16.900 17.000 17.400 0 -3.98% EUR 02:00:00  
  Frankfurt 16.894 17.100 17.544 0 -0.04% EUR 02:03:00  
  Vienna 17.300 0.000 0.000 0 0.00% EUR 21/08  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Apple 212.64 213.65 211.60 +2.28 +1.08% 21.56M 21/08  
  Facebook 183.55 185.90 183.14 -0.26 -0.14% 8.41M 21/08  
  Alphabet A 1,191.58 1,200.56 1,187.92 +8.05 +0.68% 708.27K 21/08  
  Lockheed Martin 382.96 384.26 379.29 +1.21 +0.32% 711.65K 21/08  
  Tesla 220.83 223.22 217.60 -5.03 -2.23% 7.80M 21/08  
  Netflix 297.81 302.88 296.20 -1.18 -0.39% 5.69M 21/08  
  Amazon.com 1,823.54 1,829.58 1,815.00 +22.16 +1.23% 2.04M 21/08  
  Microsoft 138.79 139.49 138.00 +1.53 +1.11% 14.98M 21/08  
  Alibaba ADR 175.19 178.50 174.89 -2.02 -1.14% 9.38M 21/08  
  IBM 134.34 135.94 133.84 +1.34 +1.01% 2.71M 21/08  

Mylan NV Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

35000

Equity Type

ORD

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Company's Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment primarily develops, manufactures, sells and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream or ointment form. The Europe segment sells pharmaceuticals under their International Nonproprietary Name (INN), such as active pharmaceutical ingredient (API), in certain European countries. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) $0 Start Trading
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MYL Comments

Write your thoughts about Mylan NV
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
João Félix
João Félix Jun 19, 2019 11:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
You can see what I wrote two years ago and see the share value evolution. .its a management problem.
Csaba Kiss
Csaba Kiss May 08, 2019 11:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This "dad cat bouncing".
Steven Hidden
Steven Hidden Feb 26, 2019 7:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2018 year end Earnings Call summary - They have some good news, but they did not flaunt it on the call.   two important areas to read 1) Statement of Free Cash Flows, almost at the very bottom of the report.  Mylan generated $87M more in free cash in 2018 over 2017.   This is a 3% gain in cash generation. Not bad given that their advair product was 6 months late.   2) Need to look at the adjusted earnings per share that also increased 2 cents a share over 2017.  They achieved this even though they have 3 hardships A) Epipen lost patent protection and now there are many generics on the market  B) their Advair genereric was delayed by almost 6 months, and that was the primary reason why they could not keep the top line strong while epipen sales dropped .. but for 2019, the product is approved and selling.   3) they had huge lay-offs and restructings from plant closure..  Guidence is solid, but not amazing.  The stock should remain within its trading range of 29.50 to 31.50.
Sal Nan
Sal Nan Feb 26, 2019 7:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sounds good, esp the cash front. Seems the market thinks it's not sustainable. If a one time write off, then this could be a buy now at a 52 week low
João Félix
João Félix Sep 29, 2017 3:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mylan shareholders vote against executive pay. .Directors face strong opposition. .These group of Directors don't have the profile and competency to manage Mylan at this moment in time. That is the main problem of this company.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email